Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Are we dead in the water here?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(945)
•••
Comment by Nailbiter2on Jan 17, 2023 8:36am
139 Views
Post# 35227345

RE:RE:RE:RE:RE:RE:RE:RE:Are we dead in the water here?

RE:RE:RE:RE:RE:RE:RE:RE:Are we dead in the water here?
Nailbiter2 wrote:

EXAS' pipeline products include esophageal, breast, lung, liver, and pancreatic cancer testing. The company is also working with the Mayo Clinic to identify biomarkers associated with the 15 deadliest cancers. Other initiatives focus on:

  • Using experience gained from the development of Cologuard to create a wider cancer detection platform
  • Expanding the range Oncotype IQ products to include liquid and tissue-based tests
  • Adapting biomarker-based technologies create a liquid biopsy capable of detecting cancers and precancers from a blood sample
  • Improving analytical sensitivity using the company's existing multi-marker approach to better identify cancerous samples
  •  

 An illustration of the company's major mergers and acquisitions.

 
 
 
 
 
 
 
 
 
 

Exact Sciences Corp.
(Founded 1995)
 
 
 
 

Sampleminded
(Acq 2017)
 
 
 
 
 

Armune Bioscience
(Acq 2018)
 
 
 
 
 

Biomatrica
(Acq 2018)
 
 
 
 
 

Genomic Health
(Acq 2019)
 
 
 
 
 

Paradigm Diagnostics
(Acq 2020)
 
 
 
 
 

Viomics
(Acq 2020)
 
 
 
 
 

Thrive Earlier Detection Corp.
(Acq 2020)
 
 
 
 
 

Base Genomics
(Acq 2020)

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities